目的：探讨贝伐珠单抗联合多柔比星脂质体治疗铂类耐药复发性卵巢上皮性癌患者的近期疗效和不良反应，并随访生存情况。方法：选取中国人民解放军联勤保障部队第九〇一医院2018年1月至2019年12月收治的76例铂类耐药复发性卵巢上皮性癌患者，采用数字随机分组法分为对照组38例、观察组38例，对照组给予多柔比星脂质体单药化疗4个周期，观察组给予贝伐珠单抗联合多柔比星脂质体化疗4个周期，观察两组患者治疗后近期疗效和不良反应，以及血清肿瘤标志物人附睾蛋白4（human epididymis protein 4，HE4）、糖类抗原125（carbohydrate antigen 125，CA125）变化，并随访总生存期（OS）和无疾病进展生存期（PFS）。结果：对照组患者客观有效率（ORR）为40.54%、疾病控制率（DCR）为67.57%，观察组患者ORR为69.44%、DCR为88.89%，观察组ORR和DCR显著高于对照组（均P<0.05）。治疗后观察组患者血清HE4和CA125分别为（142.67±46.81）pmol/L、（31.79±11.65）U/L，显著低于对照组患者的（219.33±75.67）pmol/L、（57.05±17.85）U/L（均P<0.05）。两组患者的胃肠反应、骨髓抑制、肝肾功能损伤、心脏毒性、过敏反应、血栓栓塞和出血等不良反应相比较差异无统计学意义（均P>0.05）；观察组患者高血压发生率显著高于对照组（P<0.05），但可控、可耐受。观察组患者中位OS 和中位PFS分别分别为17.2个月和10.9个月，显著长于对照组患者的14.1个月和7.8个月（均P<0.05）。结论：对于铂类耐药复发性卵巢上皮性癌患者，贝伐珠单抗联合多柔比星脂质体近期疗效可靠、安全性好、不良反应可耐受，值得临床推广。

Objective: To explore the short-term efficacy and adverse reactions of bevacizumab combined with doxorubicin liposomes in the treatment of patients with platinum-resistant recurrent epithelial ovarian cancer, as well as the survival of patients. Methods: A total of 76 patients with platinum-resistant recurrent epithelial ovarian cancer who were admitted to the 901 Hospital of the People's Liberation Army (PLA) Joint Logistic Support Force from January 2018 to December 2019 were enrolled in this study. The patients were divided into a control group and an observation group with 38 cases in each by random number grouping method. The control group was given doxorubicin liposome single-agent chemotherapy for 4 cycles, while the observation group was given bevacizumab combined with doxorubicin liposome chemotherapy for 4 cycles. The short-term efficacy and adverse reactions of the two groups of patients after treatment were observed, and the changes in serum tumor markers HE4 (human epididymis protein 4) and CA125 (carbohydrate antigen 125) were detected. In addition, the patients were followed up for overall survival (OS) and disease progression[1]free survival (PFS). Results: The objective response rate (ORR) and disease control rate (DCR) of the control group were significantly lower than those of the observation group (ORR: 40.54% vs 69.44%; DCR: 67.57% vs 88.89%; all P<0.05). After treatment, the serum HE4 and CA125 levels of the observation group were (142.67±46.81) pmol/L and (31.79±11.65) U/L respectively, which were significantly lower than (219.33±75.67) pmol/L and (57.05±17.85) U/L of the control group (all P<0.05). There were no significant differences in adverse reactions such as gastrointestinal reactions, bone marrow suppression, liver and kidney damage, cardiotoxicity,allergic reactions, thromboembolism, and bleeding between the two groups (all P>0.05); the incidence of hypertension in the observation group was significantly higher than that in the control group (P<0.05), but it was controllable and tolerable. The median OS and median PFS of the patients in observation group were 17.2 months and 10.9 months respectively, which were significantly longer than the 14.1 months and 7.8 months of the control group (all P<0.05). Conclusion: For patients with platinum-resistant recurrent epithelial ovarian cancer, bevacizumab combined with doxorubicin liposomes has reliable short-term efficacy, good safety, and tolerable adverse reactions, which is worthy of clinical promotion.

（原）南京军区面上项目资助（No. 15MS049）